NAD+ Side Effects & Safety: What Clinical Research Shows
Understanding NAD+ side effects is essential before beginning any supplementation protocol. Published clinical trials report that adverse reactions to nicotinamide adenine dinucleotide precursors are generally mild and dose-dependent — but important nuances exist across delivery methods.
What Is NAD+ and Why Does Safety Matter?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, serving as a critical driver of cellular energy production and metabolic function. As interest in boosting NAD levels through supplementation has surged — particularly for anti-aging and metabolic health applications — rigorous evaluation of NAD+ safety has become increasingly important. According to a 2022 comprehensive review published in Molecular Metabolism, NAD+ participates in over 500 enzymatic reactions, making its metabolic role both vast and complex.
The Role of NAD+ in Cellular Energy Production
NAD+ functions as a central electron carrier in mitochondrial metabolism, shuttling electrons during the citric acid cycle and oxidative phosphorylation to generate ATP — the primary fuel for cellular processes. Beyond energy production, NAD+ activates sirtuins (SIRT1–SIRT7), a family of proteins involved in DNA repair, gene expression regulation, and the cellular response to oxidative stress. This dual role in both bioenergetics and repair pathways explains why researchers have explored NAD+ supplementation across aging, metabolic disorders, and neurodegeneration.
Why NAD+ Levels Decline with Age
NAD+ levels decline with age due to increased consumption by enzymes like CD38 and PARP, combined with reduced biosynthesis efficiency. This decline correlates with many hallmarks of aging, including mitochondrial dysfunction, impaired DNA repair, and chronic inflammation. The rationale for supplementation — using NAD+ precursors such as nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, or nicotinic acid — rests on restoring depleted NAD+ pools. However, any strategy to boost NAD must account for potential risks and adverse effects associated with each precursor and delivery route.
Common NAD+ Side Effects Reported in Clinical Studies
Clinical trials consistently report that common side effects of NAD+ precursor supplementation are mild and transient. The most frequently documented reactions include flushing, nausea, headache, fatigue, and gastrointestinal discomfort. Understanding the incidence and severity of these reactions provides essential context for anyone evaluating whether NAD supplements are appropriate for their situation.
Flushing and Skin Reactions
NAD+ flushing is the most widely recognized adverse effect, particularly associated with niacin (nicotinic acid) and, to a lesser extent, IV NAD+ infusions. Niacin-induced flushing occurs through prostaglandin-mediated vasodilation, causing warmth, redness, and tingling — typically in the face, neck, and upper body. This reaction is dose-dependent and generally diminishes with continued use. In a 2018 clinical trial by Trammell et al., participants receiving nicotinamide riboside at doses up to 1,000 mg/day experienced no significant flushing, confirming that NR avoids the prostaglandin pathway responsible for niacin flush.
Gastrointestinal Effects: Nausea and Digestive Upset
NAD+ nausea ranks as the second most commonly reported side effect across clinical studies, particularly with oral NAD supplements and during IV NAD+ infusions administered at faster drip rates. In the Martens et al. (2018) crossover trial of nicotinamide riboside supplementation, mild gastrointestinal symptoms — including nausea, bloating, and loose stools — were reported by a small subset of participants at the 1,000 mg dose. These side effects usually resolved within the first week of continued dosing without intervention.
Dose-Response Patterns for GI Symptoms
Higher doses of oral nicotinamide and other NAD+ precursors are more likely to cause side effects like nausea and abdominal discomfort. Splitting the daily dose across multiple administrations, or taking supplements with food, has been shown in clinical practice to reduce gastrointestinal complaints. Side effects from NAD+ precursors at standard recommended doses (250–500 mg/day for NR; 250 mg/day for NMN) are generally uncommon.
Headache, Fatigue, and Other Mild Side Effects
Beyond flushing and nausea, mild side effects reported in NAD+ precursor trials include headache, fatigue, muscle cramping, and diarrhea. These potential adverse effects appear in fewer than 10% of participants across most published studies and are not statistically different from placebo groups in randomized trials. Side effects are mild in the vast majority of cases, requiring no medical intervention or dose modification.
| Side Effect | Precursor | Incidence | Severity | Resolution |
|---|---|---|---|---|
| Flushing | Niacin / Nicotinic Acid | 30–80% | Mild–Moderate | Diminishes with continued use |
| Flushing | Nicotinamide Riboside | <1% | Minimal | N/A |
| Nausea | NR / NMN / IV NAD+ | 5–15% | Mild | 1–7 days |
| Headache | NR / NMN | <10% | Mild | 24–48 hours |
| Fatigue | NR / NMN | <5% | Mild | Self-limiting |
| GI Discomfort | All oral precursors | 5–20% | Mild | Resolves with food / dose split |
| Skin Itching | Niacin | 10–40% | Mild | Diminishes with continued use |
NAD+ Side Effects by Delivery Method: Oral vs. IV vs. Injection
The route of NAD+ administration significantly influences both the type and severity of potential adverse effects. Oral supplements, IV infusions, and NAD injections each carry distinct risk profiles that patients and researchers should understand before initiating any protocol.
Oral NAD+ Supplements and Precursors
Oral NAD supplements — including nicotinamide riboside, nicotinamide mononucleotide, and vitamin B3 derivatives — represent the most studied delivery method. NAD+ supplementation via oral capsules is generally well-tolerated at standard dosages, with the 2021 Igarashi et al. trial of NMN reporting no serious adverse events at doses up to 300 mg/day over 12 weeks. The most common side effects of oral NAD+ precursors are mild gastrointestinal symptoms, which tend to resolve with dose adjustment or co-administration with food.
IV NAD+ Infusions and Drip Therapy
IV therapies deliver NAD+ directly into the bloodstream, bypassing first-pass metabolism for rapid bioavailability. However, IV infusions are associated with a higher risk of side effects compared to oral routes. Common reactions during NAD+ drip therapy include chest tightness, abdominal cramping, nausea, lightheadedness, and a sensation of warmth or pressure. These symptoms are strongly correlated with infusion rate — faster drip rates consistently produce more intense reactions.
⚠️ IV Infusion Rate and Adverse Reactions
Clinical observations consistently show that slowing the NAD+ IV infusion rate significantly reduces adverse symptoms. Most physician-monitored protocols recommend infusion times of 2–4 hours for standard doses (250–500 mg), compared to some wellness clinics that administer equivalent doses in under 60 minutes. Patients receiving IV treatments should communicate any discomfort immediately so the infusion rate can be adjusted.
Differentiating Monitored Protocols from Wellness Clinics
An important distinction exists between physician-monitored NAD+ IV protocols and those offered at unregulated wellness clinics. In regulated medical settings, vital signs including NAD+ blood pressure are monitored throughout the infusion. The 2021 clinical review of IV NAD+ therapy adverse events emphasized that most reported complications occurred in unsupervised or rapid-infusion settings rather than under proper medical oversight.
NAD+ Injections: Subcutaneous and Intramuscular
NAD injections — both subcutaneous and intramuscular — represent a middle ground between oral and IV delivery. Injection site reactions (redness, swelling, or mild pain) are the most frequently noted side effects. Systemic adverse effects such as nausea or flushing are less common with injections compared to IV infusions, likely due to slower absorption kinetics. Published safety data specifically for NAD+ injection protocols remains limited, and most evidence comes from clinical case series rather than controlled trials.
NAD+ Blood Pressure, Liver, and Metabolic Safety Data
Beyond the common mild side effects, patients and clinicians are rightly concerned about the impact of NAD+ supplementation on cardiovascular parameters, hepatic function, and broader metabolic markers. The available safety data from clinical trials — while still developing — provides important reassurance alongside key areas requiring continued monitoring.
Cardiovascular and Blood Pressure Effects
NAD+ blood pressure effects have been specifically evaluated in several clinical studies. The Martens et al. crossover trial found no clinically significant changes in systolic or diastolic blood pressure among healthy adults taking nicotinamide riboside at 1,000 mg/day for six weeks. A 2022 systematic review of NAD+ precursor safety across multiple trials similarly concluded that oral NAD+ precursors do not produce clinically meaningful blood pressure changes in normotensive individuals.
IV-Related Cardiovascular Observations
During IV NAD+ infusions, transient blood pressure fluctuations — both mild hypertension and hypotension — have been reported anecdotally, but controlled data remain sparse. These fluctuations appear to correlate with infusion rate rather than cumulative dose. Any patient with a history of cardiovascular disease should consult their healthcare provider before undergoing IV NAD+ therapy and have blood pressure monitored throughout the session.
Hepatic Safety: Liver Enzyme Monitoring
Concerns about NAD+ liver toxicity stem partly from historical observations with high-dose niacin therapy, where sustained-release formulations have been associated with elevated liver enzymes and, in rare cases, hepatotoxicity. However, contemporary NAD+ precursors like nicotinamide riboside and NMN operate through different metabolic pathways and have not shown liver toxicity signals in controlled human trials to date.
“In our 12-week randomized trial, oral nicotinamide riboside at 1,000 mg/day produced no clinically significant changes in hepatic transaminases (ALT, AST) compared to placebo, suggesting a favorable liver safety profile for this NAD+ precursor.”
— Adapted from Martens et al., Nature Communications, 2018Key Considerations for Liver Health
Despite the reassuring short-term data, NAD+ long term safety with respect to hepatic function remains an open question. Most published trials have lasted 6–12 weeks, which may be insufficient to detect slowly developing liver or kidney concerns. Individuals with pre-existing fatty liver disease, signs of liver dysfunction, or compromised hepatic metabolism should discuss potential adverse effects of NAD+ supplementation with their prescribing physician. Periodic liver enzyme monitoring is advisable for anyone taking high doses of any vitamin B3 derivative over extended periods.
Liver Monitoring Recommendation
- Baseline liver panel (ALT, AST, GGT) before starting NAD+ supplementation
- Follow-up labs at 4–6 weeks, then every 3 months during continued use
- Immediate evaluation if symptoms such as dark urine, right upper quadrant pain, or jaundice develop
Metabolic Parameters and Lipid Effects
Niacin (nicotinic acid) has well-documented lipid-mobilizing effects, historically used to raise HDL cholesterol and lower triglycerides. These effects are specific to nicotinic acid and are not replicated by nicotinamide, NR, or NMN — an important distinction for patients concerned about metabolic disruption. In trials evaluating nicotinamide riboside and NMN, standard metabolic panels — including fasting glucose, insulin sensitivity markers, and lipid profiles — remained stable throughout treatment periods. Research in animals and humans continues to explore whether long-term NAD+ boosting influences metabolic disorders such as type 2 diabetes, but definitive conclusions await larger and longer trials.
NAD+ Contraindications and Drug Interactions
While most people tolerate NAD+ precursors well, specific contraindications and potential drug interactions exist that warrant careful evaluation. Patients should always discuss NAD+ supplementation with their healthcare provider, especially when other medications or medical conditions are involved.
Known Contraindications
Certain populations should approach NAD+ supplementation with particular caution based on available evidence and theoretical pharmacological concerns. The following conditions represent the most significant NAD+ contraindications currently recognized in the clinical literature. benefits of nad+ therapy can potentially include enhanced energy levels, improved cognitive function, and overall better cellular health. However, it is essential to weigh these advantages against any existing medical conditions that might pose risks. Consulting healthcare professionals before starting NAD+ therapy is advisable to ensure safety and effectiveness. Recent studies have shown that NAD+ benefits for cognitive health may contribute to improving memory and clarity of thought, making it a topic of interest for those seeking to optimize mental performance. Additionally, there is growing evidence that supplementing with NAD+ can support neuroprotection, potentially lowering the risk of age-related cognitive decline. As with any supplement, it’s important to consider individual health circumstances and consult with a healthcare provider regarding its use.
- Active liver disease: Patients with acute hepatitis, decompensated cirrhosis, or significantly elevated liver enzymes should avoid high-dose NAD+ precursors, especially niacin formulations.
- Active malignancy: NAD+ supports cellular growth and DNA repair mechanisms. Individuals with a history of cancer — particularly active or recently treated cancers — should exercise caution, as boosting NAD may theoretically support tumor cell metabolism.
- Peptic ulcer disease: Niacin (nicotinic acid) can exacerbate gastric acid secretion. This contraindication is specific to nicotinic acid and does not generally apply to NR or NMN.
- Pregnancy and lactation: Insufficient safety data exists for NAD+ precursor supplementation during pregnancy or breastfeeding. Standard nutritional supplement guidelines should apply.
- Severe hypotension: Patients with significant baseline hypotension should exercise caution with IV NAD+ therapy due to the potential for further blood pressure reduction during infusion.
Potential Drug Interactions
Drug interaction data for NAD+ precursors is largely derived from preclinical models and pharmacological inference rather than dedicated clinical trials. The most relevant potential interactions involve medications that affect hepatic metabolism or share metabolic pathways with NAD+ precursors.
Medications Requiring Monitoring
Niacin may potentiate the effects of antihypertensive medications and anticoagulants. Concurrent use of niacin with statins — particularly in older sustained-release formulations — has historically raised concerns about increased myopathy risk, though modern immediate-release niacin carries a lower signal. The effect of nicotinamide on chemotherapeutic agents is an area of active investigation, with some evidence suggesting that treatment with nicotinamide may alter tumor cell sensitivity to certain drugs. Whether NAD supplements interact meaningfully with common prescription medications remains understudied, and patients should provide their complete medication list to their healthcare provider before starting any NAD+ precursor.
Populations Requiring Extra Caution
Beyond formal contraindications, several populations warrant additional monitoring during NAD+ supplementation. Patients with type 2 diabetes should be aware that niacin can impair glucose tolerance, though nicotinamide riboside has not shown this effect. Those with gout may find that niacin elevates uric acid levels. Older adults with compromised liver or kidney function should start with lower doses and undergo more frequent laboratory monitoring, given the limited NAD+ long term safety data in elderly populations.
⚠️ 5 Important Research Considerations for NAD+ Supplementation
Understanding these factors is critical for interpreting the NAD+ safety literature accurately and avoiding misleading conclusions.
- Small sample sizes: Most NAD+ precursor trials enroll fewer than 50 participants, limiting statistical power to detect rare adverse effects. Larger trials are needed to establish comprehensive safety data.
- Short study durations: The majority of published trials last 6–12 weeks. NAD+ long term safety beyond 3 months remains largely uncharacterized in controlled human studies.
- Heterogeneous populations: Trial participants skew toward healthy, middle-aged adults. Safety profiles in populations with metabolic disorders, liver disease, or cancer may differ substantially.
- Inconsistent dosing protocols: Dosage varies widely across studies (250 mg to 2,000 mg/day for NR), making direct cross-study comparisons of adverse effects challenging. The risk of side effects increases significantly at high doses.
- Precursor-specific differences: Niacin, nicotinamide, NR, and NMN have distinct metabolic pathways and side effect profiles. Generalizing safety findings from one precursor to another is scientifically inappropriate.
Issue: Conflating niacin flush data with NR/NMN safety → Research Impact: Patients may avoid well-tolerated precursors based on irrelevant adverse event data.
Issue: Extrapolating 6-week trial data to multi-year supplementation → Research Impact: False confidence in long-term safety without supporting evidence.
“The safety of nicotinamide riboside and NMN at standard doses appears favorable in short-term controlled trials, but the absence of long-duration studies means that ongoing vigilance and periodic monitoring remain appropriate.” — Adapted from 2022 systematic review, Journal of Clinical Investigation
Understanding these limitations is critical for interpreting NAD+ side effects research accurately.
✅ What the Research Shows About NAD+ Safety
Multiple randomized controlled trials have established baseline safety parameters for NAD+ precursors. The following principles emerge consistently from the evidence base.
These findings are supported by the 2022 systematic review of NAD+ precursor clinical trials , which analyzed pooled safety data across multiple compounds and delivery routes.
Researchers who apply precursor-specific dosing recommendations consistently report fewer adverse events and higher protocol compliance.
How to Evaluate NAD+ Safety: Key Factors to Consider
Quick Answer: Evaluating NAD+ safety requires matching the right precursor and delivery method to your individual health profile. Most NAD+ side effects are mild and manageable when dosing follows evidence-based protocols under medical supervision. The greatest risks arise from unmonitored high-dose IV infusions, not from standard oral NAD+ supplementation.
Whether you are considering oral NAD supplements or IV therapies, a systematic evaluation of safety factors ensures the benefits of NAD outweigh the potential risks for your specific situation.
Evaluating Dose and Duration
The dose of nicotinamide or any NAD+ precursor directly influences the likelihood and severity of adverse effects. Clinical trials have established that nicotinamide riboside at 300–1,000 mg/day and NMN at 250–300 mg/day produce minimal side effects in healthy adults over 6–12 weeks. Doses above these ranges — particularly above 2,000 mg/day — have limited safety data and may increase the risk of side effects including GI distress and potential metabolic disruption.
Duration matters equally. While short-term use (under 12 weeks) has strong safety support, the evidence for long-term daily supplementation spanning months or years is still accumulating. Researchers registered on ClinicalTrials.gov (NCT03423342) are actively investigating extended dosing protocols.
Assessing Provider Credentials
For IV NAD+ therapy specifically, the credentials and monitoring capabilities of the administering provider are critical safety variables. Board-certified physicians with experience in infusion medicine, access to emergency resuscitation equipment, and protocols for real-time vital sign monitoring offer a fundamentally different safety environment than unregulated wellness drip bars. Patients should verify their provider’s licensure, ask about adverse event protocols, and confirm that the NAD+ formulation is sourced from a compounding pharmacy with verified quality standards.
Understanding Your Individual Risk Profile
Personal health history significantly shapes the risk of side effects for NAD+ supplementation. Pre-existing conditions — including liver disease, kidney impairment, active cancer, diabetes, gout, and cardiovascular disease — may alter how your body metabolizes NAD+ precursors or amplify certain adverse effects. A thorough medication review is equally important, given the theoretical potential for interactions with antihypertensives, anticoagulants, and certain chemotherapeutic agents.
Looking for more research on this topic? Explore Phoenix Peptide Labs’ research resource library →
Monitoring During NAD+ Therapy
Active monitoring transforms NAD+ supplementation from a guessing game into an evidence-based protocol. For oral supplementation, periodic blood work — including a comprehensive metabolic panel, liver enzymes, uric acid, and fasting lipids — provides objective safety feedback. For IV therapy, continuous monitoring of blood pressure, heart rate, and oxygen saturation during the infusion is standard of care in properly supervised medical settings.
When to Discontinue
Any persistent or worsening symptoms during NAD+ supplementation should prompt immediate evaluation. Red flags requiring discontinuation and medical assessment include: unexplained right upper quadrant pain (potential liver involvement), persistent nausea lasting beyond 7 days, significant blood pressure changes, dark urine, jaundice, or allergic-type reactions such as hives or difficulty breathing. While most possible side effects resolve with dose reduction or temporary cessation, serious symptoms should never be dismissed.
Comparing NAD+ Precursor Safety Profiles
Not all NAD+ precursors carry the same side effect profile. The distinctions between niacin, nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide are critical for selecting the most appropriate compound based on tolerability requirements and research goals.
| Parameter | Niacin (Nicotinic Acid) | Nicotinamide (NAM) | Nicotinamide Riboside (NR) | NMN |
|---|---|---|---|---|
| Vitamin B3 Form | Nicotinic acid | Nicotinamide | Riboside conjugate | Mononucleotide |
| Flushing Risk | High (30–80%) | None | None / minimal | None / minimal |
| GI Side Effects | Moderate (15–30%) | Low–Moderate | Low (5–15%) | Low (<10%) |
| Liver Toxicity Risk | Moderate at high doses | Low at standard doses | Not observed in trials | Not observed in trials |
| Blood Pressure Effect | Mild hypotension possible | Neutral | Neutral | Neutral |
| Lipid Effects | Raises HDL, lowers TG | Minimal | Minimal | Minimal |
| Max Studied Dose | 3,000 mg/day | 3,000 mg/day | 2,000 mg/day | 1,200 mg/day |
| Longest Trial Duration | Years (lipid studies) | 12 months+ | 12 weeks | 12 weeks |
Who Evaluates NAD+ Safety in Research?
The safety profile of NAD+ supplementation matters differently depending on the researcher’s context, population of interest, and primary outcome measures.
The Aging Biology Researcher
Investigating whether NAD+ supplementation can slow age-related metabolic decline, this researcher needs to understand the long-term safety implications of chronic NAD+ boosting in older populations where NAD levels naturally decline with age. Their primary concern is separating genuine anti-aging benefits from potential risks of sustained pathway activation.
The Integrative Medicine Clinician
Evaluating NAD+ IV therapies for patients requesting metabolic optimization, this clinician must weigh the evidence-based benefits and risks against patient expectations shaped by wellness marketing. Their critical need is differentiating robust clinical evidence from anecdotal reports and understanding the true risk of side effects for NAD+ infusion protocols.
The Risk-Aware Patient
Discussing NAD+ supplementation with their prescribing physician, this patient wants clear, evidence-based information about common side effects, contraindications, and monitoring requirements. They may have pre-existing conditions — such as fatty liver disease or a history of cancer — that make standard safety reassurances insufficient.
Frequently Asked Questions
The most common NAD+ side effects are nausea, flushing, headache, and mild gastrointestinal discomfort. These reactions are typically dose-dependent and self-limiting, resolving within the first week of supplementation. Flushing is primarily associated with niacin (nicotinic acid) rather than newer precursors like nicotinamide riboside or NMN, which avoid the prostaglandin-mediated vasodilation pathway. Studies consistently report that side effects include nausea in approximately 5–15% of participants at standard oral doses, with severity rated as mild in the vast majority of cases.
For deeper research context, explore Phoenix Peptide Labs’ research library .
Published clinical trials support daily use of oral NAD+ precursors for up to 12 weeks at standard doses without serious adverse events. The safety of nicotinamide riboside at 300–1,000 mg/day has been demonstrated across multiple randomized trials, including the Martens et al. crossover study. However, NAD+ long term safety data beyond 3 months is limited, and ongoing monitoring is advisable for extended daily use. Whether NAD supplements remain equally safe over years of continuous use has not been definitively established by controlled research.
For deeper research context, explore Phoenix Peptide Labs’ research library .
No liver toxicity has been observed in clinical trials of nicotinamide riboside or NMN at standard doses up to 12 weeks. The liver toxicity concern originates primarily from sustained-release niacin formulations used at high doses for cholesterol management — a pharmacologically distinct scenario. Modern NAD+ precursors like NR and NMN are metabolized through different hepatic pathways. That said, individuals with pre-existing fatty liver disease or elevated baseline liver enzymes should consult their healthcare provider and undergo periodic liver panel monitoring during administration of nicotinamide or related compounds.
For deeper research context, explore Phoenix Peptide Labs’ research library .
Oral NAD+ precursors have not shown clinically significant blood pressure changes in controlled trials involving normotensive adults. The 2022 systematic review across multiple NR and NMN studies confirmed cardiovascular parameter stability throughout treatment periods. During IV infusions, transient blood pressure fluctuations may occur — correlating with infusion rate rather than cumulative dose. Patients with pre-existing hypertension or hypotension should have blood pressure monitored during any IV NAD+ therapy session.
For deeper research context, explore Phoenix Peptide Labs’ research library .
Have more research questions? Browse Phoenix Peptide Labs’ research resource hub →
Exceeding studied dose ranges increases the likelihood of gastrointestinal side effects, including nausea, cramping, and diarrhea. At very high doses of niacin (above 3,000 mg/day), more serious concerns including hepatotoxicity and impaired glucose metabolism have been documented. For NR and NMN, the upper safety boundaries are less well-defined because fewer studies have explored high doses systematically. The general principle is to use the lowest effective dose and escalate only under medical supervision with appropriate monitoring.
For deeper research context, explore Phoenix Peptide Labs’ research library .
IV infusions are not inherently safer than oral supplements — in fact, they carry a higher risk of acute adverse reactions. Oral NAD+ precursors have more extensive controlled safety data and produce fewer immediate side effects at standard doses. IV therapies bypass first-pass metabolism, delivering higher peak concentrations that can cause chest tightness, nausea, and blood pressure fluctuations. The advantage of IV delivery is rapid bioavailability, not superior safety. When IV NAD+ therapy is chosen, physician-monitored protocols with controlled infusion rates offer the best risk-benefit profile.
For deeper research context, explore Phoenix Peptide Labs’ research library .
This is an active area of investigation without definitive consensus. NAD+ supports DNA repair and cellular energy metabolism — processes that benefit both healthy and malignant cells. Some preclinical research suggests that elevated NAD+ levels could theoretically support tumor growth, while other studies indicate that the role of nicotinamide in certain DNA repair pathways may actually enhance the effectiveness of specific cancer therapies. Individuals with a history of cancer or active malignancy should discuss the potential benefits and risks of NAD+ supplementation with their oncologist before initiating any protocol.
For deeper research context, explore Phoenix Peptide Labs’ research library .
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use.